View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 26, 2021

Aptabio to initiate Phase II oral Covid-19 therapy trial

South Korean company Aptabio is all set to initiate a Phase II trial of its oral therapy, APX-115, for treating Covid-19.

South Korean company Aptabio is all set to initiate a Phase II trial of its oral therapy, APX-115, for treating Covid-19.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

A transmembrane enzyme NADPH oxidase (NOX) inhibitor, APX-115 was studied in Europe for treating patients with diabetes complications.

The latest development comes after the US Food and Drug Administration (FDA) granted approval to commence the trial, Pulse reported.

Clinical research organisation COVANCE will carry out the study in 80 Covid-19 patients at 12 medical centres in the US.

Aptabio noted that its APX-115 hinders NOX2 and ROS in the endosome, obstructing the virus pathway.

In December last year, the company submitted the Phase II study protocol to the FDA.

The approval to carry out the trial came rapidly owing to data from a Phase I trial in Europe, with no safety signals observed.

Aptabio intends to conclude a confirmatory clinical trial based upon positive results from the Phase II trial and will submit an application seeking emergency use authorization.

In a separate development, the Korea Disease Control and Prevention Agency (KDCA) has confirmed that GC Pharma’s plasma therapy is effective against the UK and South African variants of Covid-19.

After assessing the efficacy of the therapy against the S, L, V, G, GR, GH, and GV plus UK and South African virus genotypes, the KDCA found that the drug produced neutralising antibodies for all strains.

KDCA Deputy Director Kwon Jun-wook told Korea Biomedical Review: “We have confirmed in a cell experiment that the homegrown plasma therapy produced neutralising antibodies for all Covid-19 strains and was hardly affected by the variants.”

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena